Literature DB >> 8986008

Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics.

F I Tarazi1, W J Florijn, I Creese.   

Abstract

Quantitative in vitro receptor autoradiography was used to examine changes in three ionotropic glutamate receptor subtypes using 3H-MK801 (NMDA-R antagonist), 3H-CNQX (AMPA-R antagonist) and 3H-kainic acid (kainate-R agonist) following subchronic (28 days) and chronic (8 months) treatment of rats with a typical antipsychotic, haloperidol (1.5 mg/kg per day), atypical antipsychotic, clozapine (25 mg/kg per day), the dopamine D2/D3 receptor antagonist, raclopride (10 mg/kg per day), and the dopamine D1 (D1/D5) receptor antagonist SCH23390 (0.5 mg/kg per day). Subchronic and chronic drug treatments did not significantly alter 3H-CNQX or 3H-kainate binding in any of brain regions examined. Subchronic SCH23390 treatment elevated 3H-MK801 binding in the hippocampal formation with significant increases in the CA1 and dentate gyrus, suggesting a specific role for dopamine D1 receptors in the regulation of hippocampal NMDA receptor function. Subchronic, but not chronic, haloperidol and clozapine treatment significantly reduced 3H-MK801 binding in the medial prefrontal cortex. This suggests that typical and atypical antipsychotics may exert some of their clinical effects by affecting NMDA receptors in the medial prefrontal cortex. Both subchronic and chronic clozapine treatment decreased 3H-MK801 binding in the caudate putamen. The minimal extrapyramidal side effects produced by clozapine may result, in part, from the reduction in NMDA receptor binding in the caudate putamen.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8986008     DOI: 10.1007/s002130050147

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  13 in total

1.  Developmental vitamin D deficiency alters MK-801-induced behaviours in adult offspring.

Authors:  James P Kesby; Jonathan C O'Loan; Suzanne Alexander; Chao Deng; Xu-Feng Huang; John J McGrath; Darryl W Eyles; Thomas H J Burne
Journal:  Psychopharmacology (Berl)       Date:  2011-09-21       Impact factor: 4.530

Review 2.  Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.

Authors:  G J Lees
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

3.  Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats.

Authors:  Yasunori Oda; Yuko Fujita; Kengo Oishi; Yusuke Nakata; Masayuki Takase; Tomihisa Niitsu; Nobuhisa Kanahara; Yukihiko Shirayama; Kenji Hashimoto; Masaomi Iyo
Journal:  Psychopharmacology (Berl)       Date:  2017-07-25       Impact factor: 4.530

4.  Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits.

Authors:  Andrea Schmitt; Mathias Zink; Bettina Müller; Brigitte May; Anne Herb; Alexander Jatzko; Dieter F Braus; Fritz A Henn
Journal:  Neurochem Res       Date:  2003-02       Impact factor: 3.996

5.  Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia.

Authors:  Yong Kee Choi; Shikha Snigdha; Mohammed Shahid; Jo C Neill; Frank I Tarazi
Journal:  J Mol Neurosci       Date:  2009-05-20       Impact factor: 3.444

6.  Repeated administration of the novel antipsychotic olanzapine does not modulate NMDA-sensitive glutamate and 5HT2 serotonin receptors in rats.

Authors:  Ottavio Gandolfi; Manuela Voltattorni; Renato Gaggi; Rossella Dall'Olio
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-13       Impact factor: 3.000

7.  Effects of risperidone on glutamate receptor subtypes in developing rat brain.

Authors:  Yong Kee Choi; Matthew P Gardner; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2008-10-09       Impact factor: 4.600

8.  Altered dopamine receptor and dopamine transporter binding and tyrosine hydroxylase mRNA expression following perinatal NMDA receptor blockade.

Authors:  Teresa Marie du Bois; Ching-Wen Hsu; Yulin Li; Yean Yeow Tan; Chao Deng; Xu-Feng Huang
Journal:  Neurochem Res       Date:  2008-02-08       Impact factor: 3.996

9.  Yi-gan san restores behavioral alterations and a decrease of brain glutathione level in a mouse model of schizophrenia.

Authors:  Manabu Makinodan; Takahira Yamauchi; Kouko Tatsumi; Hiroaki Okuda; Yoshinobu Noriyama; Miyuki Sadamatsu; Toshifumi Kishimoto; Akio Wanaka
Journal:  J Brain Dis       Date:  2009-02-12

10.  Different effects of a single and repeated administration of clozapine on phencyclidine-induced hyperlocomotion and glutamate releases in the rat medial prefrontal cortex at short- and long-term withdrawal from this antipsychotic.

Authors:  Tomohiro Abekawa; Koki Ito; Tsukasa Koyama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-04-26       Impact factor: 3.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.